LDN-212854

SKU: orb1307185

Description

LDN-212854 is a selective BMP pathway inhibitor with high potency against ALK2 (IC50=1.3 nM) and distinct activity profiles towards ALK1 and ALK3. It is a valuable research tool for studying BMP signaling in vitro and has been used in vivo to investigate bone formation, heterotopic ossification, and iron metabolism pathways.

Research Area

Cardiovascular Research, Signal Transduction, Stem Cell & Developmental Biology

Key Properties

• CAS Number: 1432597-26-6
• MW: 406.48
• Purity: 99.38%
• Formula: C₂₅H₂₂N₆
• SMILES: C1CN(CCN1)c1ccc(cc1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12
• Target: TGF-beta/Smad,ALK
• Solubility: DMSO:10.42 mg/mL (25.63 mM)

Bioactivity

• Target IC50:
  ALK1:2.4 nM|ALK5:9276 nM|BMPR1A:85.8 nM|ALK2:1.3 nM|ALK4:2133 nM
• In Vivo:
  In C2C12 myoblasts, LDN-212854 demonstrates a higher selectivity for BMP6 over BMP4 in inducing osteogenic differentiation, compared to the osteogenic differentiation induced by BMP6 and BMP4.
• In Vitro:
  LDN-212854 (6 mg/kg, i.p.) effectively inactivates ALK2 signaling in vivo and efficiently inhibits ectopic ossification in inducible transgenic ALK2 mice mutants with progressive ankylosis.

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

TGF-β/Smad, TGF-β Receptor, TGFβ, TGFbeta/Smad, TGFb, TGF-b/Smad, TGFbeta, TGF-beta, Transforming growth factor beta receptors, Smad, Huh7, FOP model, EpCAM, heterotopic ossification, HCC, LDN 212854, LDN212854, LDN-212854, MT cell, inhibit, Inhibitor, ALK2, ALK1, ALK3, ALK4, ALK5, BMP, BMP Inhibitor III, BMP9-ID1 signaling, BMPR2 cell

Compound Identifiers

PubChem CID

60182388